For Doctors in a Hurry
- Detailed population-level estimates of obesity are lacking but necessary to understand demographic disparities and inform targeted clinical interventions.
- The researchers analyzed body mass index data from 11,315,421 adults using statistical models that track changes across space and time.
- Adult obesity prevalence reached 42.5% in 2022 and is projected to hit 46.9% (95% uncertainty interval, 43.9%-49.9%) by 2035.
- The authors concluded that obesity prevalence remains high and will continue increasing across all racial, ethnic, age, and state groups.
- Clinicians should anticipate a growing clinical burden, particularly among non-Hispanic Black females and middle-aged adults who face the highest prevalence.
Obesity remains one of the most pervasive drivers of chronic morbidity in clinical practice, directly contributing to hypertension, diabetes, cardiovascular disease, chronic kidney disease, and multiple malignancies [1, 2, 3, 4, 5]. Decades of epidemiological tracking have documented a steady upward trajectory in body mass index across the population, with historical data showing adult obesity prevalence climbing sharply from 13 percent in the 1960s to 32 percent by 2004 [6]. Despite widespread public health initiatives and the introduction of targeted pharmacological therapies, minority populations continue to bear a disproportionate share of this metabolic burden, experiencing annual prevalence increases of up to 0.9 percentage points [1, 6]. Anticipating future healthcare needs requires an accurate understanding of how these demographic and geographic disparities are evolving over time, given that 60 percent of the adult population is now overweight or obese [1]. A new comprehensive analysis offers updated estimates and future projections of this ongoing public health crisis to help clinicians better stratify patient risk and manage associated cardiovascular complications [7].
Massive Dataset Maps Three Decades of BMI Trends
To capture the true scale of this metabolic crisis, the study estimated United States obesity prevalence from 1990 to 2022 and predicted trends through 2035 by race and ethnicity, state, sex, and age for adults 20 years and older. The analysis included a total of 11,315,421 US participants, making it an exceptionally robust epidemiological assessment. Surveys for input data were conducted using population-based sampling by state and by race and ethnicity group. The investigators defined obesity prevalence as a body mass index (BMI) of 30 or greater. Because self-reported weight often underestimates true clinical measurements, the analysis combined measured BMI data from the National Health and Nutrition Examination Survey with bias-corrected BMI values calculated from self-reported height and weight data from the Behavioral Risk Factor Surveillance System and Gallup Daily Survey. This dual-source approach ensures that the massive volume of self-reported data is accurately calibrated against objective clinical measurements. To map these trends with high geographic and demographic precision, the researchers utilized spatiotemporal gaussian process regression and an ensemble of annualized rate of change and meta-regression bayesian spline models. In clinical terms, these advanced statistical tools allow researchers to smooth out missing data points across time and geography, creating highly granular, state-by-state predictions of how obesity rates will shift over the next decade. Using these models, the study generated detailed forecasts to help clinicians and policymakers anticipate regional healthcare demands. The final results are reported for Hispanic (any race), non-Hispanic Black, and non-Hispanic White populations, providing a detailed look at how the metabolic burden is distributed across different demographic groups.
National Prevalence Doubles, Approaching 50 Percent
The national trajectory of metabolic disease over the past three decades reveals a stark escalation in clinical burden. In 1990, there were an estimated 34.7 million (95% uncertainty interval [UI], 31.1 to 38.3 million) adults living with obesity in the US. This baseline figure meant that the 1990 obesity prevalence represented 19.3% (95% UI, 17.3% to 21.3%) of the adult population. Fast forward to the most recent data, and the landscape has fundamentally shifted. In 2022, there were an estimated 107 million (95% UI, 101 to 113 million) adults living with obesity in the US. Consequently, the 2022 obesity prevalence represented 42.5% (95% UI, 40.2% to 45.0%) of the adult population, indicating that the proportion of affected adults has more than doubled. For practicing physicians, this translates to a daily reality where nearly half of all adult patients present with elevated metabolic and cardiovascular risk profiles directly tied to adiposity. The epidemiological models suggest this upward trajectory will persist without aggressive clinical and public health interventions. By 2035, the number of adults living with obesity is projected to increase to 126 million (95% UI, 118 to 134 million). At this level, the projected 2035 obesity prevalence represents 46.9% (95% UI, 43.9% to 49.9%) of the adult population, approaching a threshold where nearly one in two adults will meet the criteria for the disease. Importantly, the researchers noted that the prevalence of obesity is forecasted to continue increasing for all groups despite large differences by race and ethnicity, sex, age, and state. This universal expansion signals that while specific demographic and geographic disparities require targeted management strategies, the overall clinical demand for obesity interventions, including glucagon-like peptide-1 (GLP-1) receptor agonists and bariatric surgery, will rise across every patient population.
Severe Disparities Emerge Across Demographics and Geography
Beneath the national averages, the 2022 data reveal profound demographic and geographic divides that directly impact clinical practice. Nationally, age-standardized prevalence by race and ethnicity group and sex in 2022 ranged from 40.1% (95% UI, 37.8% to 42.5%) for non-Hispanic White males to 56.9% (95% UI, 54.1% to 59.9%) for non-Hispanic Black females. This nearly 17-percentage-point gap underscores the disproportionate metabolic burden carried by specific patient populations. The geographic distribution of this disease also presents distinct regional challenges for healthcare systems. The researchers identified substantial state-level differences in obesity prevalence, with rates highest in Midwestern and Southern states. Furthermore, when examining local demographics, the investigators found that within-state disparities in obesity prevalence by race and ethnicity were larger for females than males. For clinicians practicing in these high-prevalence regions, these intersecting disparities necessitate highly tailored approaches to weight management and cardiovascular risk reduction, particularly for female minority patients. The epidemiological models also highlighted critical shifts across different stages of adulthood. The analysis demonstrated that obesity prevalence varied by age, being highest among middle-aged adults. While this peak in midlife aligns with established patterns of age-related metabolic slowing and cumulative lifestyle factors, the trajectory among younger cohorts presents a new clinical alarm. The data showed large increases in obesity prevalence in the youngest adult ages, especially for females. For primary care physicians and specialists, this rapid acceleration of adiposity in young adults signals an impending wave of early-onset cardiovascular and metabolic diseases, including type 2 diabetes and hypertension, occurring decades earlier than traditionally expected.
References
1. Dilokthornsakul P, Rattanachaisit N, Thimkorn P, Pongpattanawut S, Dilokthornsakul W, Dhippayom T. Clinical effects of Hibiscus sabdariffa Linn. on obesity treatment: A systematic review and meta-analysis of randomized controlled trials.. Complementary therapies in medicine. 2024. doi:10.1016/j.ctim.2024.103063
2. Hill NR, Fatoba S, Oke J, et al. Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. PLoS ONE. 2016. doi:10.1371/journal.pone.0158765
3. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018. doi:10.1093/eurheartj/ehy339
4. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal. 2019. doi:10.1093/eurheartj/ehz486
5. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA A Cancer Journal for Clinicians. 2005. doi:10.3322/canjclin.55.2.74
6. Wang Y, Beydoun MA. The Obesity Epidemic in the United States Gender, Age, Socioeconomic, Racial/Ethnic, and Geographic Characteristics: A Systematic Review and Meta-Regression Analysis. Epidemiologic Reviews. 2007. doi:10.1093/epirev/mxm007
7. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2019. doi:10.1093/eurheartj/ehz455
